| Stage | SYK | % of rev | GMED | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $6.5B | 100.00% | $790M | 100.00% | SYK ×8.26 |
| Gross profit | $4.2B | 65.15% | $548M | 69.42% | GMED +4.3pp |
| Operating income | $1.0B | 15.86% | $182M | 23.10% | GMED +7.2pp |
| Pre-tax income | $997M | 15.29% | $190M | 24.04% | GMED +8.7pp |
| Net income | $753M | 11.55% | $152M | 19.20% | GMED +7.6pp |
| Stage | SYK | GMED | Gap · A − B |
|---|---|---|---|
| Revenue | $6.5B100.00% | $790M100.00% | SYK ×8.26 |
| Gross profit | 65.15%$4.2B | 69.42%$548M | GMED +4.3pp |
| Operating income | 15.86%$1.0B | 23.10%$182M | GMED +7.2pp |
| Pre-tax income | 15.29%$997M | 24.04%$190M | GMED +8.7pp |
| Net income |
| 11.55%$753M |
| 19.20%$152M |
| GMED +7.6pp |